Catalyst

Slingshot members are tracking this event:

Phase 3 PALISADE trial of AR101 for Peanut Allergy to be completed Q4 2017

Source Link:
http://ir.aimmune.com/phoenix.zhtml?c=254097&p=irol-pressReleasesArticle&ID=2225814

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AIMT Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Aimmune expects to complete enrollment in PALISADE in the second half of 2016 and complete the trial in the second half of 2017
http://ir.aimmune.co...
Additional Relevant Details Update on June 20 2017: "Once the trial is completed, we will also be able to examine in detail the links between baseline characteristics and outcomes, from both an efficacy and a safety perspective.”
http://ir.aimmune.co...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 20, 2018
Occurred Source:
http://ir.aimmune.com/news-releases/news-release-details/aimmune-therapeutics-pivotal-phase-3-palisade-trial-ar101-meets
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Trial, Ar101, Peanut Allergy, Palisade
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.